{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007622","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.755901+00:00","generated_at":"2026-06-02T05:40:44.531150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coherus Q1 revenue $77.1M, net income $102.9M; UDENYCA +63% YoY; LOQTORZI launch underway","bullets":["Net revenue $77.1M in Q1 2024 vs $32.4M in Q1 2023; GAAP net income $102.9M ($0.83 diluted EPS) vs net loss of $75.7M.","UDENYCA net sales $42.7M, up 18% QoQ and 63% YoY; LOQTORZI launch sales $2.0M; CIMERLI divested for $187.8M cash.","Non-GAAP net loss $35.8M (-$0.32 per share), improved from non-GAAP net loss $59.5M in Q1 2023.","New debt and royalty financing replaces $75M term loan; debt maturity extended to May 2029.","Entered partnership with CRI and ENB Therapeutics to study toripalimab in ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007622","json":"https://secwatch.observer/filing/0001558370-24-007622.json","markdown":"https://secwatch.observer/filing/0001558370-24-007622.md","text":"https://secwatch.observer/filing/0001558370-24-007622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/0001558370-24-007622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/chrs-20240509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:40:44.531150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9c6543898aebe8177048235e402af56bb087dd3","claim":"Coherus Oncology, Inc. reported the quarter ended March 31, 2024 results: revenue $77.1 million, net income $102.9 million, EPS $0.83 per share on a diluted basis.","evidence_excerpt":"reference in such a filing. --- EX-99.1 (EX-99.1) --- ​ ​ ​ Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update ​ – Net revenue of $77.1 million in Q1 2024 – ​ – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – ​ – New debt and royalty financing replaces $75 million term loan, with debt","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/0001558370-24-007622-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$77.1 million"},{"label":"Net income","value":"$102.9 million"},{"label":"EPS","value":"$0.83 per share on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}